Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Terminated 2Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Multiple Endocrine Neoplasia Type 1 1Glioma 1Glioblastoma 1Coronary Disease 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × evolocumab × Clear all
NCT03872401 2025-11-10

VESALIUS-CV

Amgen

Phase 3 Completed
12,301 enrolled
Endocrine

Coronary Disease, Multiple Endocrine Neoplasia Type 1

NCT04937413 2024-06-25

The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

Duke University

Phase EARLY_PHASE1 Completed
32 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡